XPO1 inhibitor for lymphoma, extranodal nk-t-cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Apr 2023: Trial registered, NCT05833893

The trials

NCT05833893: Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

State
Under way
Phase
Phase 2
People
10 planned
Started
1 May 2023
Primary completion
31 Dec 2025
Arms
Treatment group
Results
None posted
  1. 27 Apr 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.